Autolus Therapeutics presents clinical data updates at Tandem Meetings

Autolus Therapeutics (AUTL) announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, being held from February 12-15, 2025, in Hawai’i Convention Center, Honolulu, HI. Oral: Title: Risk Factors Associated with Sub-Optimal Outcomes and Hematotoxicity Following Obecabtagene Autoleucel or Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Summary: Risk-stratification for hematotoxicity, using pre-LD clinical parameters together with disease burden, has potential use for identifying patients more likely to benefit from obe-cel treatment and experience reduced toxicity. Patients with low-risk hematotoxicity scores had consistently better outcomes than patients with high-risk hematotoxicity scores. Abstract 24949 – Poster: Title: An Economic Model Comparing the Costs Associated with Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Among Patients Treated with Chimeric Antigen Receptor T-Cell Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Summary: A decision tree economic model was developed using rates and median durations of AEs reported in the FELIX and ZUMA-3 trials. Obe-cel was associated with lower CRS- and ICANS-related healthcare costs versus brexu-cel, primarily due to lower rates of Gr 3/4 AEs and faster resolution of these events. These results suggest that obe-cel improves resource utilization and reduces healthcare costs versus other CAR T-cell therapies for R/R B-ALL. Abstract 26113 – Poster: Title: Comparison of Obecabtagene Autoleucel Versus an External Control Arm in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Summary: The study was designed to report efficacy and safety outcomes of obe-cel in FELIX patients vs. patients treated with non-CAR T-cell standard of care therapies in a matched External Control Arm. Obe-cel demonstrated higher ORR and longer OS and EFS vs. SOC in matched ECAs. Safety was comparable between treatment groups, demonstrating a positive benefit-risk profile of obe-cel for treatment of adult R/R B-ALL. Abstract 26366 – Poster: Title: Deep Molecular Remission Predicts Better Clinical Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Obecabtagene Autoleucel: Summary: Among obe-cel responders for whom measurable residual disease by next-generation sequencing could be analyzed, 84% achieved MRD less than10-6 leukemic cells, which was associated with more durable responses, and higher EFS and OS rates than patients with MRD greater than or equal to10-4 and MRD between 10-4 and 10-6 leukemic cells. Patients who did not achieve MRD less than10-6 had poorer outcomes.